T-lymphocyte concentrations of cholecystokinin-8 and beta-endorphin in eating disorders: II. Bulimia nervosa.
Concentrations of cholecystokinin-8 (CCK-8) and beta-endorphin (beta-EP) in T-lymphocytes of 26 women with bulimia nervosa (BN) and in 26 age- and sex-matched healthy comparison subjects were measured. Ten patients were then treated with 300 mg/day of fluvoxamine, p.o., and five patients were treated with 300 mg/day of amineptine, p.o., for 4 months. Concentrations of the two peptides were measured again after 1, 2, and 4 months of therapy. Basal CCK-8 values were significantly lower in patients than in healthy subjects. During fluvoxamine therapy, CCK-8 values increased, reaching normal levels by month 4 of treatment. No such increase occurred during amineptine therapy. Baseline beta-EP values were normal in the bulimic patients but had declined by month 4 of fluvoxamine therapy.
Brambilla
F
F
Psychoneuroendocrine Center, Ospedale Pini, Milan, Italy.
Brunetta
M
M
Draisci
A
A
Peirone
A
A
Perna
G
G
Sacerdote
P
P
Manfredi
B
B
Panerai
A E
AE
D000293:Adolescent; D000328:Adult; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage; D002032:Bulimia / Q000097:blood* / Q000628:therapy; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D003986:Dibenzocycloheptenes / Q000008:administration & dosage; D005260:Female; D016666:Fluvoxamine / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage; D012844:Sincalide / Q000097:blood*; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism*; D016896:Treatment Outcome; D001615:beta-Endorphin / Q000097:blood*
D000929:Antidepressive Agents, Tricyclic; D003986:Dibenzocycloheptenes; D016666:Fluvoxamine; D017367:Selective Serotonin Reuptake Inhibitors; D012844:Sincalide; D001615:beta-Endorphin; C011597:amineptin